Expert Opinion on Investigational Drugs

SJR Rank #3,637H-index: 126SJR: 1.199Best quartile: Q1

Journal website: aims, scope and author guidelines

Publisher

Taylor and Francis Ltd.

Country

United Kingdom

Type

journal

SJR by Edition

Subject Categories

Medicine (miscellaneous)Q1
PharmacologyQ1
Pharmacology (medical)Q1

Areas: Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Monoclonal and Polyclonal Antibodies ResearchDiabetes Treatment and ManagementAsthma and respiratory diseasesLipoproteins and Cardiovascular HealthHIV/AIDS drug development and treatmentHER2/EGFR in Cancer ResearchNeurotransmitter Receptor Influence on BehaviorImmunotherapy and Immune ResponsesCancer Treatment and PharmacologyAngiogenesis and VEGF in Cancer

Source: OpenAlex

Publication Statistics

Documents per Year

Detailed Information

ISSN

1354-3784, 1744-7658

SJR Best Quartile

Region

Western Europe

Citations per Document (2 years)

4.22

References per Document

76.77

Coverage

1994-2026

Scope

Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Metrics from SCImago Journal Rank 2025. View on SCImago